Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMQWR4N)

Drug Name	PR001 DMQWR4N
Drug Type	Gene therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 1/2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Gaucher disease	DISTW5JG	5C56.0Y	Phase 1/2	[1]
Parkinson disease	DISQVHKL	8A00.0	Phase 1/2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04411654) An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose LY3884961 in Infants With Type 2 Gaucher Disease. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04127578) A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL). U.S.National Institutes of Health.